GROWTH-HORMONE TREATMENT OF ABDOMINALLY OBESE MEN REDUCES ABDOMINAL FAT MASS, IMPROVES GLUCOSE AND LIPOPROTEIN METABOLISM, AND REDUCES DIASTOLIC BLOOD-PRESSURE
G. Johannsson et al., GROWTH-HORMONE TREATMENT OF ABDOMINALLY OBESE MEN REDUCES ABDOMINAL FAT MASS, IMPROVES GLUCOSE AND LIPOPROTEIN METABOLISM, AND REDUCES DIASTOLIC BLOOD-PRESSURE, The Journal of clinical endocrinology and metabolism, 82(3), 1997, pp. 727-734
The most central findings in both GH deficiency in adults and the meta
bolic syndrome are abdominal/visceral obesity and insulin resistance.
Abdominal obesity is associated with blunted GH secretion and low seru
m insulin-like growth factor-I concentrations. GH treatment in GH-defi
cient adults has demonstrated favorable effects on most of the feature
s of GH deficiency in adults, but it is not known whether GH can impro
ve some of the metabolic aberrations observed in abdominal/visceral ob
esity. Thirty men, 48-66 yr old, with abdominal/visceral obesity were
treated with recombinant human GH (rhGH) in a 9-month randomized, doub
le-blind, placebo-controlled trial. The daily dose of rhGH was 9.5 mu
g/kg. Body fat was assessed from total body potassium, and abdominal s
c and visceral adipose tissue was measured using computed tomography.
The glucose disposal rate (GDR) was measured during an euglycemic, hyp
erinsulinemic glucose clamp. In response to the rhGH treatment, total
body fat and abdominal sc and visceral adipose tissue decreased by 9.2
+/- 2.4%, 6.1 +/- 3.2%, and 18.1 +/- 7.6%, respectively. After an ini
tial decrease in the GDR at 6 weeks, the GDR increased in the rhGH-tre
ated group as compared with the placebo-treated one (P < 0.05). The me
an serum concentrations of total cholesterol (P < 0.01) and triglyceri
de (P < 0.05) decreased, whereas blood glucose and serum insulin conce
ntrations were unaffected by the rhGH treatment. Furthermore, diastoli
c blood pressure decreased and systolic blood pressure was unchanged i
n response to rhGH treatment. This trial has demonstrated that GH can
favorably affect some of the multiple perturbations associated with ab
dominal/visceral obesity. This includes a reduction in abdominal/visce
ral obesity, an improved insulin sensitivity, and favorable effects on
lipoprotein metabolism and diastolic blood pressure.